Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721598 | 0.93 | TSHR (0.42) | AKR1B1KDM1AHTR2ATSHRTDP1 | |
| SCHEMBL28442386 | 0.87 | TSHR (0.44) | AKR1B1KDM1AHTR2ATSHRTDP1 | |
| SCHEMBL23855524 | 0.87 | TSHR (0.44) | AKR1B1KDM1AHTR2ATSHRTDP1 | |
| SCHEMBL29386234 | 0.87 | TSHR (0.44) | AKR1B1KDM1AHTR2ATSHRTDP1 | |
| SCHEMBL29674233 | 0.81 | HTR2A (0.47) | AKR1B1KDM1AHTR2ATSHRTDP1 | |
| SCHEMBL22541598 | 0.81 | HTR2A (0.47) | AKR1B1KDM1AHTR2ATSHRTDP1 | |
| SCHEMBL2244008 | 0.78 | HTR2A (0.41) | KDM1AHTR2A | |
| SCHEMBL30817682 | 0.77 | PDE7A (0.39) | AKR1B1HTR2AKMT2A | |
| SCHEMBL30747315 | 0.77 | TNKS (0.45) | KDM1A | |
| SCHEMBL14522963 | 0.76 | HTR2A (0.51) | AKR1B1KDM1AHTR2ATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404922-B1 | QUINOXALINE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2016-11-09 | — | — | EP | disclosed |
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8674096-B2 | Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2615089-A1 | PYRAZOLOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| EP-2404922-A1 | QUINOXALINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | AKR1B1 1065/4885KDM1A 560/4885HTR2A 3728/4885 |
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | AKR1B1 757/4885KDM1A 643/4885HTR2A 3820/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | AKR1B1 1530/4885KDM1A 493/4885HTR2A 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.